Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
The latest update is out from COMPASS Pathways ( (CMPS) ).
On July 28, 2025, Compass Pathways appointed Justin Gover to its Board of Directors, effective July 29, 2025. Gover, with over 25 years of experience in the biopharmaceutical industry, will serve as a Class III director and join the audit and risk and scientific committees. His appointment comes as the company enters a critical phase following the achievement of the primary endpoint in their first Phase 3 trial for COMP360, positioning Compass as a leading company in the psychedelic treatment space. This transition also includes the retirement of Dr. Linda McGoldrick, who has been instrumental in guiding the company through its IPO and early clinical milestones.
The most recent analyst rating on (CMPS) stock is a Buy with a $23.00 price target. To see the full list of analyst forecasts on COMPASS Pathways stock, see the CMPS Stock Forecast page.
Spark’s Take on CMPS Stock
According to Spark, TipRanks’ AI Analyst, CMPS is a Neutral.
Compass Pathways demonstrates potential due to its strong equity position and progress in clinical trials. However, significant financial risks due to a lack of revenue and increasing operational costs weigh heavily on its performance. The stock’s upward momentum is promising, but valuation remains challenging due to negative profitability. The recent earnings call underscores both strategic progress and financial challenges, which tempers the overall outlook.
To see Spark’s full report on CMPS stock, click here.
More about COMPASS Pathways
Compass Pathways plc is a biotechnology company focused on accelerating patient access to evidence-based innovation in mental health. They are pioneering a new paradigm for treating mental health conditions through the development of their investigational COMP360 synthetic psilocybin treatment, which has received Breakthrough Therapy designation from the US FDA and Innovative Licensing and Access Pathway designation in the UK for treatment-resistant depression.
Average Trading Volume: 2,639,475
Technical Sentiment Signal: Sell
Current Market Cap: $403M
For detailed information about CMPS stock, go to TipRanks’ Stock Analysis page.